Avalon GloboCare (ALBT) Competitors $2.41 +0.15 (+6.64%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$3.60 +1.19 (+49.38%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. MBRX, HOTH, EDSA, NXTC, CARM, ATHA, NEUP, MTEX, ALLR, and LPTXShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Moleculin Biotech (MBRX), Hoth Therapeutics (HOTH), Edesa Biotech (EDSA), NextCure (NXTC), Carisma Therapeutics (CARM), Athira Pharma (ATHA), Neuphoria Therapeutics (NEUP), Mannatech (MTEX), Allarity Therapeutics (ALLR), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors Moleculin Biotech Hoth Therapeutics Edesa Biotech NextCure Carisma Therapeutics Athira Pharma Neuphoria Therapeutics Mannatech Allarity Therapeutics Leap Therapeutics Moleculin Biotech (NASDAQ:MBRX) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Is MBRX or ALBT more profitable? Moleculin Biotech has a net margin of 0.00% compared to Avalon GloboCare's net margin of -647.29%. Avalon GloboCare's return on equity of 0.00% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -278.80% -100.11% Avalon GloboCare -647.29%N/A -50.13% Do analysts prefer MBRX or ALBT? Moleculin Biotech currently has a consensus target price of $4.00, suggesting a potential upside of 484.37%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of MBRX or ALBT? 15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 2.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, MBRX or ALBT? Moleculin Biotech has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Does the media refer more to MBRX or ALBT? In the previous week, Moleculin Biotech had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 4 mentions for Moleculin Biotech and 3 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.29 beat Moleculin Biotech's score of -0.07 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalon GloboCare 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, MBRX or ALBT? Avalon GloboCare has higher revenue and earnings than Moleculin Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$21.76MN/AN/AAvalon GloboCare$1.33M3.42-$7.90M-$19.96-0.12 SummaryMoleculin Biotech beats Avalon GloboCare on 7 of the 13 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.28M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.71%4.14%P/E Ratio-0.1217.5328.8923.88Price / Sales3.42313.17447.6498.82Price / CashN/A42.6035.6858.35Price / Book-0.217.828.165.60Net Income-$7.90M-$54.52M$3.25B$265.26M7 Day Performance15.87%2.86%1.12%-0.15%1 Month Performance-11.56%17.29%8.22%6.07%1 Year Performance-42.41%13.27%29.12%24.21% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.171 of 5 stars$2.41+6.6%N/A-45.5%$4.28M$1.33M-0.125Short Interest ↑MBRXMoleculin Biotech2.7198 of 5 stars$0.55-2.9%$4.00+626.9%-71.6%$17.13MN/A0.0020Upcoming EarningsShort Interest ↑HOTHHoth Therapeutics2.7631 of 5 stars$1.31+2.3%$4.00+205.3%+119.4%$16.91MN/A-1.154News CoverageUpcoming EarningsEDSAEdesa Biotech1.7436 of 5 stars$2.33-2.1%$5.00+114.6%-53.5%$16.71MN/A-1.4720News CoveragePositive NewsUpcoming EarningsNXTCNextCure4.3721 of 5 stars$5.54-10.2%$33.00+495.7%-71.3%$16.51MN/A-0.2690Upcoming EarningsGap DownCARMCarisma Therapeutics2.3806 of 5 stars$0.37-5.9%$1.93+427.0%-65.2%$16.21M$19.63M-0.2320Gap DownATHAAthira Pharma3.0692 of 5 stars$0.41-9.9%$11.25+2,625.3%-88.2%$16.12MN/A-0.2040Upcoming EarningsGap UpNEUPNeuphoria Therapeutics1.1979 of 5 stars$8.69+2.2%$21.00+141.7%N/A$15.98M$10K0.00N/AMTEXMannatechN/A$8.05-3.4%N/A+14.0%$15.84M$117.87M-80.45250Upcoming EarningsGap DownALLRAllarity Therapeutics2.9446 of 5 stars$1.12+9.8%$9.00+703.6%-77.6%$15.38MN/A0.0010High Trading VolumeLPTXLeap Therapeutics1.8956 of 5 stars$0.34-5.6%$3.38+893.8%-84.2%$14.91MN/A-0.2040Upcoming EarningsGap Down Related Companies and Tools Related Companies Moleculin Biotech Competitors Hoth Therapeutics Competitors Edesa Biotech Competitors NextCure Competitors Carisma Therapeutics Competitors Athira Pharma Competitors Neuphoria Therapeutics Competitors Mannatech Competitors Allarity Therapeutics Competitors Leap Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts